HC Wainwright reiterates Buy rating on Zenas BioPharma, keeps $44 target
HC Wainwright reiterated its Buy rating and $44 price target. The note says the target implies 66.7% upside from the Oct. 12 close of $26.40.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.